Marit Sjo Lorentzen

Chief Operating Officer at ARCTICZYMES TECHNOLOGIES ASA

Net worth: 55 306 $ as of 2024-03-30

56 year

Health Technology

Consumer Services

Profile

Marit Sjo Lorentzen is currently the Director at Biotec BetaGlucans AS and the Vice President-Operations at ArcticZymes Technologies ASA. She has an undergraduate degree from the University of Tromso.

Known holdings in public companies

Company	Date	Number of shares	Valuation	Valuation date
ARCTICZYMES TECHNOLOGIES ASA 0.04%	2023-03-30	20,331 ( 0.04% )	55 306 $	2024-03-30

Marit Sjo Lorentzen active positions

Companies	Position	Start
ARCTICZYMES TECHNOLOGIES ASA	Chief Operating Officer	-
Biotec BetaGlucans AS Biotec BetaGlucans AS Pharmaceuticals: MajorHealth Technology Part of Lallemand, Inc., Biotec BetaGlucans AS is a Norwegian company that specializes in developing M-Gard®, an immunomodulator that enhances the body's defense mechanisms against pathogens. The private company is based in Tromsø, Norway. The technology behind M-Gard® has been successfully developed for alternative indications and applications, including nutraceuticals, wound care, and immunotherapy. The CEO of the company is Jethro Holter. Biotec BetaGlucans was acquired by Danstar Ferment AG from ArcticZymes Technologies ASA on December 31, 2020 for $7.93 million.	Director/Board Member	-

All active positions of Marit Sjo Lorentzen

Training of Marit Sjo Lorentzen

University of Tromso

Undergraduate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Marit Sjo Lorentzen's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	1
ARCTICZYMES TECHNOLOGIES ASA	Health Technology

Private companies	1
Biotec BetaGlucans AS Biotec BetaGlucans AS Pharmaceuticals: MajorHealth Technology Part of Lallemand, Inc., Biotec BetaGlucans AS is a Norwegian company that specializes in developing M-Gard®, an immunomodulator that enhances the body's defense mechanisms against pathogens. The private company is based in Tromsø, Norway. The technology behind M-Gard® has been successfully developed for alternative indications and applications, including nutraceuticals, wound care, and immunotherapy. The CEO of the company is Jethro Holter. Biotec BetaGlucans was acquired by Danstar Ferment AG from ArcticZymes Technologies ASA on December 31, 2020 for $7.93 million.	Health Technology